Xeris Biopharma Holdings (XERS) Other Non-Current Assets (2020 - 2026)

Xeris Biopharma Holdings' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• Quarterly Other Non-Current Assets changed 0.47% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (changed 0.47% YoY) and the FY2025 annual result came in at $5.2 million, down 3.46% from the prior year.
• Other Non-Current Assets was $5.1 million for Q1 2026 at Xeris Biopharma Holdings, down from $5.2 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $5.5 million in Q2 2024 and bottomed at $2.2 million in Q3 2022.
• A 5-year average of $4.5 million and a median of $4.8 million in 2023 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 928.44% — and 2025, when it dropped 7.86%.
• Xeris Biopharma Holdings' Other Non-Current Assets stood at $4.7 million in 2022, then fell by 4.02% to $4.5 million in 2023, then advanced by 19.1% to $5.4 million in 2024, then slipped by 3.46% to $5.2 million in 2025, then decreased by 1.88% to $5.1 million in 2026.
• Business Quant data shows XERS's Other Non-Current Assets at $5.1 million in Q1 2026, $5.2 million in Q4 2025, and $5.3 million in Q3 2025.